ZYUS Life Sciences Corporation (TSXV:ZYUS)
0.500
-0.020 (-3.85%)
At close: Apr 28, 2026
ZYUS Life Sciences Revenue
ZYUS Life Sciences had revenue of 105.00K CAD in the quarter ending September 30, 2025, a decrease of -14.63%. This brings the company's revenue in the last twelve months to 465.00K, up 2.88% year-over-year. In the year 2024, ZYUS Life Sciences had annual revenue of 481.00K with 37.04% growth.
Revenue (ttm)
465.00K
Revenue Growth
+2.88%
P/S Ratio
86.58
Revenue / Employee
n/a
Employees
n/a
Market Cap
40.26M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 481.00K | 130.00K | 37.04% |
| Dec 31, 2023 | 351.00K | 53.00K | 17.79% |
| Dec 31, 2022 | 298.00K | 91.00K | 43.96% |
| Dec 31, 2021 | 207.00K | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| LSL Pharma Group | 26.80M |
| Rubicon Organics | 59.45M |
| iAnthus Capital Holdings | 196.87M |
| Optimi Health | 193.60K |
| C21 Investments | 45.62M |
| MediPharm Labs | 45.12M |
| BioNxt Solutions | 15.82K |
| Mountain Valley MD Holdings | 57.00K |
ZYUS Life Sciences News
- 3 months ago - ZYUS Life Sciences Announces LIFE Offering of a minimum of C$15 Million and maximum of C$16 Million of Units - GlobeNewsWire
- 3 months ago - ZYUS Life Sciences Reports Preliminary Results from Ongoing Phase 2a UTOPIA-1 Trial Evaluating Novel Non-Opioid Pain Drug - PRNewsWire
- 8 months ago - ZYUS Life Sciences Activates First Clinical Site and Enrolls First Patient in Phase 2a UTOPIA-1 Cancer Pain Trial - PRNewsWire
- 10 months ago - ZYUS Life Sciences Strengthens Clinical Leadership with Appointment of Chief Medical Officer to Support Phase 2 Oncology Pain Trial - Business Wire
- 10 months ago - Brent H. Zettl Provides Update on Holdings of ZYUS Life Sciences Corporation - Business Wire
- 10 months ago - ZYUS Life Sciences Announces Closing of Unit Offering - Business Wire
- 11 months ago - ZYUS Life Sciences Announces Closing of First Tranche of Unit Offering - Business Wire
- 1 year ago - ZYUS Life Sciences Finalizing Site Initiation for Phase 2A Clinical Trial Advancing Novel Non-Opioid Pain Drug - Business Wire